Alzheimer's disease is the most common cause of dementia, a group of conditions marked by progressive loss of memory, reasoning, and independent function. The Alzheimer's Association estimates that more than 7 million Americans aged 65 and older are living with Alzheimer's dementia in 2026, or about 1 in 9 people in that age group. Prevalence rises steeply with age, from 5.2% of people aged 65 to 74 to 35.8% of those aged 85 and older.
The burden extends beyond patients. Projected 2026 payments for health care, long-term care, and hospice for people with the disease reach US$ 409 billion in the United States, and nearly 13 million unpaid caregivers provide care. Globally, the World Health Organization (WHO) estimated that about 57 million people lived with dementia in 2021, with Alzheimer's disease accounting for 60% to 70% of cases. These figures define the clinical and economic need that treatment developers address.
Market Introduction
Treatment options have long been limited to drugs that ease symptoms. The market is now changing as disease-modifying antibody therapies enter clinical use and as earlier diagnosis becomes possible. Rising numbers of older people, higher health care spending, and sustained research investment support demand, with attention also turning to non-drug measures such as cognitive stimulation and lifestyle changes.
As per Coherent Market Insights, the Global Dementia and Alzheimer's Disease Treatment Market is valued at US$ 14.20 Billion in 2026 and is projected to reach US$ 25.53 Billion by 2033, growing at a compound annual growth rate (CAGR) of 8.7% during the forecast period of 2026 to 2033.
3 Key Market Trends
- Growth of disease-modifying antibodies: Anti-amyloid antibodies have moved from trials into routine practice. Eli Lilly reported Kisunla revenue of US$ 167 million in the second quarter of 2026, compared with US$ 49 million a year earlier, while Leqembi added a subcutaneous at-home option, Iqlik, with an FDA approval for initiation dosing in July 2026. The market impact is a gradual shift in spending from older symptomatic drugs toward higher-priced biologics, together with demand for infusion capacity and monitoring.
- Blood-based diagnostics: Blood tests have made it easier to detect those individuals that could potentially have amyloid pathology prior to the visit to the specialists. In 2025, FDA approved the Elecsys pTau181 test by Roche. The Elecsys pTau217 test, co-developed by Lilly, was FDA-approved in 2026. Expanding the testing among the primary care population expands the patient base eligible for treatment.
- Shift toward new targets and delivery: Tau-based therapies and antibody drugs intended to penetrate the blood-brain barrier more effectively are under investigation by developers. There has been a mixed success, since the drug diranersen, being tested by Biogen, failed to meet its primary goal in a Phase 2 trial in May 2026, and in March 2026, Johnson & Johnson discontinued posdinemab development. However, Roche was able to push trontinemab into a Phase 3 trial. The impact on the industry will be a more prudent approach to investment, focused on biomarker-supported programs.
Dementia and Alzheimer's Disease Treatment Market Insights
In terms of drug classes, cholinesterase inhibitors dominate the market, taking up 30.2% of the share in 2026. The drugs decrease the destruction of acetylcholine, which is responsible for memory, and consist of donepezil, rivastigmine, and galantamine. In terms of routes, oral administration takes 33.2% of the market, since tablets, capsules, and liquids can be administered at home, while hospital pharmacies occupy 29.2% of the market among distribution channels due to the involvement of pharmacists.
The North America region leads the market with a share of 38.3% in 2026 because of healthcare infrastructure, the level of awareness about neurodegenerative diseases, and development of the leading companies. Asia Pacific ranks second with a share of 28.2%, with the fastest-growing rate due to the aging population in Japan, China, and South Korea, as well as investments in the healthcare sector. In Germany, according to the Robert Koch Institute, dementia cases will grow from 1.7 million in 2023 to 3 million in 2070.
Market Segmentation
The Dementia and Alzheimer's Disease Treatment Market is segmented by drug class, route of administration, distribution channel, gender, patient demographics, and region:
- By Drug Class: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Antidepressants, Antipsychotics, Disease-Modifying Therapies, Combination Drugs, and Others.
- By Route of Administration: Oral, Parenteral, and Transdermal.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
- By Gender
- By Patient Demographics
- By Region: North America (U.S., Canada), Latin America (Brazil, Argentina, Mexico, and the rest of the region), Europe (Germany, U.K., Spain, France, Italy, Russia, and the rest of the region), Asia Pacific (China, India, Japan, Australia, South Korea, Association of Southeast Asian Nations (ASEAN), and the rest of the region), Middle East (Gulf Cooperation Council (GCC) countries, Israel, and the rest of the region), and Africa (South Africa, North Africa, and Central Africa).
Detailed Sub-Segment Analysis
-
Cholinesterase Inhibitors (By Drug Class segment)
Cholinesterase inhibitors are estimated to hold 30.2% of the market in 2026, the largest share on the drug-class axis. Donepezil, rivastigmine, and galantamine are prescribed for mild to moderate disease, and the FDA-approved Zunveyl, a galantamine prodrug, has added a newer option. Established clinical use, oral formats, and the availability of generics keep the class widely prescribed, even as antibody therapies take a growing share of new spending.
-
Hospital Pharmacies (By Distribution Channel segment)
Hospital pharmacies are estimated to account for 29.2% of the market in 2026, the largest channel. Pharmacists in this setting guide dosing, monitor adverse effects, and coordinate with neurologists, which matters for complex regimens and for infused antibody therapies that require scheduled monitoring. As more patients start disease-modifying treatment, hospital and infusion-based dispensing is expected to remain central to the channel mix.
U.S. Country Analysis
The U.S. is the main source of demand within North America, which holds 38.3% of the global market in 2026. According to the Alzheimer's Association, 7.4 million of the people who suffer from the disease in the United States are aged 65 or over, and the cost of care payments in 2026 amounts to US$ 409 billion. Three FDA approvals have affected the treatment environment. In July 2024, the drugs Zunveyl and Kisunla received their approvals, while in August 2025, Leqembi was granted approval on its subcutaneous maintenance dosing using the drug Iqlik, and then, in July 2026, an approval on initiation dosing was announced. Clearances for blood-test diagnosis in October 2025 and August 2026 will help transfer the diagnosis to the primary care level.
Prominent Players in the Dementia and Alzheimer's Disease Treatment Industry
1. Biogen
Biogen is headquartered in Cambridge, Massachusetts. It co-markets Leqembi (lecanemab) with Eisai and records its 50% share of product revenue as collaboration revenue. The antibody was approved in the European Union in April 2025 for patients who are not ApoE e4 homozygotes, and the FDA approved the Leqembi Iqlik autoinjector for weekly maintenance in August 2025.
Biogen stopped Aduhelm (aducanumab) in January 2024 and refocused on Leqembi and tau-directed programs. In May 2026, its Phase 2 CELIA trial of diranersen missed the primary dose-response endpoint, although slower decline was seen across doses, and the company plans a registrational program.